George Kim
Overview
Explore the profile of George Kim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
725
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
22.
A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients
Laquente B, Lopez-Martin J, Richards D, Illerhaus G, Chang D, Kim G, et al.
BMC Cancer
. 2017 Feb;
17(1):137.
PMID: 28202004
Background: The aim of this study was to determine whether checkpoint kinase 1 inihibitor (CHK1), LY2603618, and gemcitabine prolong overall survival (OS) compared to gemcitabine alone in patients with unresectable...
23.
Azad N, El-Khoueiry A, Yin J, Oberg A, Flynn P, Adkins D, et al.
Oncotarget
. 2017 Feb;
8(21):35326-35338.
PMID: 28186961
Purpose: Therapy with demethylating agent 5-azacitidine and histone deacetylase inhibitor entinostat shows synergistic re-expression of tumor-suppressor genes and growth inhibition in colorectal (CRC) cell lines and in vivo studies. Experimental...
24.
Khan M, Moreno A, Joseph N, Kim G, Fimmel C
ACG Case Rep J
. 2017 Feb;
4:e21.
PMID: 28184378
Relapse of hepatitis C virus (HCV) genotype 1 infection after combination therapy with sofosbuvir and ledipasvir is unusual. We report a treatment-naïve, non-cirrhotic patient in whom the relapse of genotype...
25.
Acosta A, Senseng C, Kim G, Sekosan M, Ree N
APMIS
. 2016 May;
124(8):719-22.
PMID: 27197712
No abstract available.
26.
Hubbard J, Kim G, Borad M, Johnson E, Qin R, Lensing J, et al.
Invest New Drugs
. 2015 Nov;
34(1):96-103.
PMID: 26581401
Background: A previous phase II trial in patients with chemorefractory metastatic colorectal cancer demonstrated a 63 % disease control rate with a combination of bevacizumab and sorafenib. This phase I...
27.
Jacobsen P, Lee J, Fulp W, Siegel E, Shibata D, Laronga C, et al.
J Oncol Pract
. 2014 Oct;
11(1):e103-9.
PMID: 25352389
Purpose: Identifying and addressing psychosocial concerns is increasingly recognized as an important aspect of cancer care that needs to be improved. As part of the Florida Initiative for Quality Cancer...
28.
Laronga C, Gray J, Siegel E, Lee J, Fulp W, Fletcher M, et al.
J Am Coll Surg
. 2014 Aug;
219(4):638-45.e1.
PMID: 25086813
Background: The Florida Initiative for Quality Cancer Care (FIQCC), composed of 11 practice sites across Florida, conducted its initial evaluation of adherence to breast cancer quality of care indicators (QCI)...
29.
Srivastava G, Renfro L, Behrens R, Lopatin M, Chao C, Soori G, et al.
Oncologist
. 2014 Apr;
19(5):492-7.
PMID: 24710310
The Oncotype DX colon cancer assay is a clinically validated predictor of recurrence risk in stage II colon cancer patients. This prospective study evaluated the impact of recurrence score (RS)...
30.
Siegel E, Jacobsen P, Lee J, Malafa M, Fulp W, Fletcher M, et al.
J Am Coll Surg
. 2013 Nov;
218(1):16-25.e1-4.
PMID: 24275073
Background: The quality of cancer care has become a national priority; however, there are few ongoing efforts to assist medical oncology practices in identifying areas for improvement. The Florida Initiative...